Novigenix supports the healthcare community in saving lives through early detection of cancer


Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy.
Novigenix’s technology is based on a new generation of gene expression profiles of circulating blood cells and tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures provide new and accurate solutions for the early detection of cancer.


Sahar Hosseinian, PhD
Biostatistician and Clinical Program Manager

Sylvain Monnier-Benoit, PhD
Product Development Program Manager

Laura Ciarloni, PhD
Clinical Development Manager

Maria Quiros
Senior Accountant and Office Manager

Nicolas Demierre, PhD MBA
Chief Operating Officer

Prof. Curzio Rüegg, MD
Director of Translational Medicine

Brian B Hashemi, PhD MBA
Executive Chairman

Christian Jauch
Chief Financial Officer

Medical Advisors

Prof. Peter Bauerfeind, MD
Specialist in Gastroenterology, Clinic for Gastroenterology and Hepatology, University Hospital, Zurich (USZ), Switzerland

Prof. Gian Dorta, MD
Specialist in Gastroenterology, Department of Internal Medicine, Section Gastroenterology and Hepatology, Academic Medical Center, Lausanne (CHUV), Switzerland

Dr. Philippe Maerten, MD PhD
Specialist in Gastroenterology, Lausanne, Switzerland

Dr. Cristina Nichita, MD
Specialist in Gastroenterology, Department of Internal Medicine, Section Gastroenterology and Hepatology, Academic Medical Center, Lausanne (CHUV), Switzerland


Colorectal Cancer


Colorectal cancer is the second leading cause of cancer mortality in men and women in Europe1. The number of cases is expected to increase over the next two decades as a result of the aging population. This high mortality rate is due to the silent development of the disease as symptoms appear only in late stages when therapeutic response is poor. When detected early, colorectal cancer is highly curable and may be prevented through removal of precursor lesions known as adenomatous polyps.

Most colorectal cancers develop slowly over several years. They often start as benign precursor lesions and develop over time into colorectal cancer. Localized tumors confined to the wall of the colon are often curable with surgery. Over 90% of patients diagnosed at this early stage can survive the disease. However, if left untreated, the cancer will spread, reducing the survival rate to 70%. Once the cancer metastasizes the survival rate is further reduced to 10%2.

The European Commission3 and the Ligue Suisse Contre le Cancer4 recommend regular screening beginning at the age of 50 for average-risk populations as an essential measure for early diagnosis and intervention of colorectal cancer. Recommended tools for colorectal cancer screening in Europe currently include colonoscopy and fecal occult blood tests. Unfortunately, however, the fraction of the population at risk that accepts these tests is alarmingly low due to lack of convenience and fear of invasive procedures, swhich is leading to an unnecessary and preventable high incidence and mortality rate of colorectal cancer.

Novigenix is committed to supporting patients and the healthcare community at large by providing a simple and effective blood-based test to reduce incidence and mortality of colorectal cancer through early detection of the disease.
1) World Health Organization, International Agency for Research on Cancer, GLOBOCAN2012: Estimated Cancer Incidence, Mortality, and Prevelance Worldwide in 2012 
2) Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Fatima A. Haggar et al.  Clin Colon Surg. Nov 2009 22(4): 191-197
3) European guidelines for quality assurance in colorectal cancer screening and diagnosis
4) Ligue Suisse Contre Le Cancer 

Our solution


colox logo

Colox® is a a new generation blood-based test for early detection of colorectal cancer. It is clinically validated and currently available through clinical laboratories in Switzerland. Colox® has proven to have significant benefits:

  • It accurately and reliably detects both adenomatous polyps and early stages of colorectal cancer,
  • It offers a convenient solution for patients to be tested with no need for bowel or stool preparation,
  • It can be ordered by the physician as part of a routine medical check-up,

Colox® has been validated through a multi-center clinical study in Switzerland detecting 78% of colorectal cancer patients, and 52% of patients with adenomatous polyps. Less than 1 out of 10 people without any colorectal lesion tested positive5. Individuals testing positive with Colox® have high probability to present colorectal lesions and are referred for follow-up diagnostic colonoscopy for final diagnosis. Individuals testing negative with Colox® have no colorectal lesion with high probability and should continue periodic testing at intervals recommended by their physician.

Brochure for patients download

Brochure for physicians download

5) L. Ciarloni, S. Hosseinian Ehrensberger, N. Imaizumi, S. Monnier-Benoit, C. Nichita, S. Myung, J. Kim, S. Song, T. Kim, B. van der Weg, R. Meier, J. Borovicka, C. Beglinger, C. Vallet, P. Maerten, C. Ruegg, and G. Dorta. Development and clinical validation of a blood test based on 29-gene expression for early detection of colorectal cancer. Clin Cancer Res, 10.1158/1078-0432.CCR-15-2057

How does Colox® work?

Colox® is based on the analysis of peripheral blood mononuclear cells (PBMCs) isolated from a routine blood sample. PBMCs are responsive to growing adenomatous polyps and colorectal carcinomas as part of the “host-response”6.

Colox® measures the combined response of gene expression profile of 29 biomarkers by real-time PCR in PBMCs and the concentration of 2 protein tumor markers in plasma. The biomarker measurement data are interpreted by Novigenix’s proprietary algorithm which generates the Colox® test result. This algorithm is based on classifier combinations derived from state-of-the art mathematical analytical methods that underpin the reliability of the test7.

Colox® is available as a laboratory-developed test and is highly adaptable to standard medical laboratory workflows. Colox® is also available as a CE-IVD kit.


6) C. Nichita, L. Ciarloni, S. Monnier-Benoit, S. Hosseinian, G. Dorta, C. Ruegg. A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer; Aliment Pharmacol Ther. 2014 Mar; 39(5):507-17
7) L. Ciarloni, S. Hosseinian, S. Monnier-Benoit, N. Imaizumi, G. Dorta, C. Ruegg. Discovery of a 29-Gene Panel in Peripheral Blood Mononuclear Cells for the Detection of Colorectal Cancer and Adenomas Using High Throughput Real-Time PCR; PLoS ONE 10(4): e0123904, 2015 

How can I be tested with Colox®?

Please contact your physician to see if Colox® is suitable for you. Colox® is currently available through our partners medical laboratories in Switzerland:

Unilabs logo
Unilabs Lausanne
Rue de la Vigie 5
Tel. 021 321 40 00
Fax. 021 321 40 40
Dr Risch logo
Labormedizinisches Zentrum Dr Risch
Waldeggstrasse 37, 3097 Liebefeld
Tel. 058 523 34 00
Fax.058 523 34 99


Contact us


Novigenix SA
Biopôle IV
Route de la Corniche 3B
CH-1066 Epalinges


Phone +41 (0)21 552 07 30
Fax +41 (0)21 552 07 31

Would you like to know more about Novigenix? Please fill the form below:

Name (mandatory)

Your email (mandatory)


Your message


Please copy the code as seen in the image above:

Novigenix SA gives no warranty, nor accepts any liability in connection with the utilization of the content of this website as well as for the relevance, correctness and completeness of the information published on the website. This also applies to links which refer directly or indirectly to this website. Novigenix SA reserves the right to amend or supplement the information provided. Technical specifications, availability, processes and product range are subject to change.